743 related articles for article (PubMed ID: 22806632)
1. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.
van Heerebeek L; Hamdani N; Falcão-Pires I; Leite-Moreira AF; Begieneman MP; Bronzwaer JG; van der Velden J; Stienen GJ; Laarman GJ; Somsen A; Verheugt FW; Niessen HW; Paulus WJ
Circulation; 2012 Aug; 126(7):830-9. PubMed ID: 22806632
[TBL] [Abstract][Full Text] [Related]
2. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
3. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction.
Hamdani N; Paulus WJ; van Heerebeek L; Borbély A; Boontje NM; Zuidwijk MJ; Bronzwaer JG; Simonides WS; Niessen HW; Stienen GJ; van der Velden J
Eur Heart J; 2009 Aug; 30(15):1863-72. PubMed ID: 19487234
[TBL] [Abstract][Full Text] [Related]
4. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction.
Hamdani N; Bishu KG; von Frieling-Salewsky M; Redfield MM; Linke WA
Cardiovasc Res; 2013 Mar; 97(3):464-71. PubMed ID: 23213108
[TBL] [Abstract][Full Text] [Related]
5. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction.
Franssen C; Chen S; Unger A; Korkmaz HI; De Keulenaer GW; Tschöpe C; Leite-Moreira AF; Musters R; Niessen HW; Linke WA; Paulus WJ; Hamdani N
JACC Heart Fail; 2016 Apr; 4(4):312-24. PubMed ID: 26682792
[TBL] [Abstract][Full Text] [Related]
6. Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction.
Kato N; Kinugawa K; Shiga T; Hatano M; Takeda N; Imai Y; Watanabe M; Yao A; Hirata Y; Kazuma K; Nagai R
J Cardiol; 2012 Jul; 60(1):23-30. PubMed ID: 22445598
[TBL] [Abstract][Full Text] [Related]
7. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction.
Paulus WJ; Dal Canto E
JACC Heart Fail; 2018 Jan; 6(1):1-7. PubMed ID: 29284577
[TBL] [Abstract][Full Text] [Related]
8. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
Brouwers FP; de Boer RA; van der Harst P; Voors AA; Gansevoort RT; Bakker SJ; Hillege HL; van Veldhuisen DJ; van Gilst WH
Eur Heart J; 2013 May; 34(19):1424-31. PubMed ID: 23470495
[TBL] [Abstract][Full Text] [Related]
9. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
[TBL] [Abstract][Full Text] [Related]
10. Shunxin decoction improves diastolic function in rats with heart failure with preserved ejection fraction induced by abdominal aorta constriction through cyclic guanosine monophosphate-dependent protein kinase Signaling Pathway.
Jiaying Z; Xiangxiang W; Xuefeng LI; Yang Y; Yinghuan D; Yanbin S; Ping X; Mengru Z; Junnan Z; Miao LI; Shuwen Z; Rui Z; Ying T; Hao T; Feifei T
J Tradit Chin Med; 2022 Oct; 42(5):764-772. PubMed ID: 36083484
[TBL] [Abstract][Full Text] [Related]
11. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
12. Causes and pathophysiology of heart failure with preserved ejection fraction.
Kovács Á; Papp Z; Nagy L
Heart Fail Clin; 2014 Jul; 10(3):389-98. PubMed ID: 24975903
[TBL] [Abstract][Full Text] [Related]
13. Cardiomyocyte stiffness in diastolic heart failure.
Borbély A; van der Velden J; Papp Z; Bronzwaer JG; Edes I; Stienen GJ; Paulus WJ
Circulation; 2005 Feb; 111(6):774-81. PubMed ID: 15699264
[TBL] [Abstract][Full Text] [Related]
14. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
[TBL] [Abstract][Full Text] [Related]
15. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
Schwartzenberg S; Redfield MM; From AM; Sorajja P; Nishimura RA; Borlaug BA
J Am Coll Cardiol; 2012 Jan; 59(5):442-51. PubMed ID: 22281246
[TBL] [Abstract][Full Text] [Related]
16. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
Mohammed SF; Hussain S; Mirzoyev SA; Edwards WD; Maleszewski JJ; Redfield MM
Circulation; 2015 Feb; 131(6):550-9. PubMed ID: 25552356
[TBL] [Abstract][Full Text] [Related]
17. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort.
Quiroz R; Doros G; Shaw P; Liang CS; Gauthier DF; Sam F
Am J Cardiol; 2014 Feb; 113(4):691-6. PubMed ID: 24484862
[TBL] [Abstract][Full Text] [Related]
18. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.
Maeder MT; Kaye DM
Int J Cardiol; 2012 Mar; 155(2):249-56. PubMed ID: 21035207
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
Cheng RK; Cox M; Neely ML; Heidenreich PA; Bhatt DL; Eapen ZJ; Hernandez AF; Butler J; Yancy CW; Fonarow GC
Am Heart J; 2014 Nov; 168(5):721-30. PubMed ID: 25440801
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
